Cargando…

Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients

Natural killer (NK) cells represent a key component of the innate immune system against cancer. Nevertheless, malignant diseases arise in immunocompetent individuals despite tumor immunosurveillance. Hodgkin lymphoma (HL) is characterized by CD30(+) tumor cells and a massive infiltration of immune e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reiners, Katrin S., Kessler, Jörg, Sauer, Maike, Rothe, Achim, Hansen, Hinrich P., Reusch, Uwe, Hucke, Christian, Köhl, Ulrike, Dürkop, Horst, Engert, Andreas, von Strandmann, Elke Pogge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616527/ https://www.ncbi.nlm.nih.gov/pubmed/23459515 http://dx.doi.org/10.1038/mt.2013.14

Ejemplares similares

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies
por: Shatnyeva, Olga M., et al.
Publicado: (2015)

Hodgkin Lymphoma-Derived Extracellular Vesicles Change the Secretome of Fibroblasts Toward a CAF Phenotype
por: Dörsam, Bastian, et al.
Publicado: (2018)

Role of Exosomes Released by Dendritic Cells and/or by Tumor Targets: Regulation of NK Cell Plasticity
por: Reiners, Katrin S., et al.
Publicado: (2014)

CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro
por: Hansen, Hinrich P., et al.
Publicado: (2016)

Cancer-derived extracellular vesicles: friend and foe of tumour immunosurveillance
por: Dörsam, Bastian, et al.
Publicado: (2018)

Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function
por: Simhadri, Venkateswara Rao, et al.
Publicado: (2008)

Evidence of Inbreeding in Hodgkin Lymphoma
por: Thomsen, Hauke, et al.
Publicado: (2016)

Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset
por: Kloess, Stephan, et al.
Publicado: (2017)

Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset
por: Kloess, Stephan, et al.
Publicado: (2018)

Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids
por: Klöss, Stephan, et al.
Publicado: (2015)

The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC
por: Ponath, Viviane, et al.
Publicado: (2020)

The Role of Extracellular HSP70 in the Function of Tumor-Associated Immune Cells
por: Linder, Manuel, et al.
Publicado: (2021)

Extracellular vesicle measurements with nanoparticle tracking analysis – An accuracy and repeatability comparison between NanoSight NS300 and ZetaView
por: Bachurski, Daniel, et al.
Publicado: (2019)

Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles
por: Ponath, Viviane, et al.
Publicado: (2021)

Antigen Loss Variants: Catching Hold of Escaping Foes
por: Vyas, Maulik, et al.
Publicado: (2017)

Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation
por: Vyas, Maulik, et al.
Publicado: (2017)

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

Beyond the Extracellular Vesicles: Technical Hurdles, Achieved Goals and Current Challenges When Working on Adipose Cells
por: Gómez-Serrano, María, et al.
Publicado: (2021)

RIG-I activation induces the release of extracellular vesicles with antitumor activity
por: Daßler-Plenker, Juliane, et al.
Publicado: (2016)

Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53
por: Schuldner, Maximiliane, et al.
Publicado: (2019)

Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude
por: Borchmann, Sven, et al.
Publicado: (2017)

Molecular Determinants for RNA Release into Extracellular Vesicles
por: Mosbach, Marie-Luise, et al.
Publicado: (2021)

Epigenetic Regulation of Airway Epithelium Immune Functions in Asthma
por: Alashkar Alhamwe, Bilal, et al.
Publicado: (2020)

TRAIL-dependent apoptosis of peritoneal mesothelial cells by NK cells promotes ovarian cancer invasion
por: Steitz, Anna Mary, et al.
Publicado: (2023)

Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin’s Lymphoma
por: Frampton, Matthew, et al.
Publicado: (2013)

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30(+) tumor cells
por: Reusch, Uwe, et al.
Publicado: (2014)

Intein mediated high throughput screening for bispecific antibodies
por: Hofmann, Tim, et al.
Publicado: (2020)

The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
por: Worzfeld, Thomas, et al.
Publicado: (2017)

Late domain dependent E-cadherin recruitment into extracellular vesicles
por: Bänfer, Sebastian, et al.
Publicado: (2022)

KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP
por: Alkhayer, Reem, et al.
Publicado: (2023)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
por: Tavarozzi, Rita, et al.
Publicado: (2022)

An Il12-Il2-Antibody Fusion Protein Targeting Hodgkin's Lymphoma Cells Potentiates Activation Of Nk And T Cells For An Anti-Tumor Attack
por: Jahn, Tobias, et al.
Publicado: (2012)

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
por: Wang, Zhaoming, et al.
Publicado: (2021)

Therapy-Related Myeloid Neoplasms in Patients Treated for Hodgkin Lymphoma
por: Eichenauer, D.A., et al.
Publicado: (2011)

Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility
por: Sud, Amit, et al.
Publicado: (2017)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
por: Rajendran, Sakthi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r4ir4fl4vok66da368v6eubvkm